Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Ivosidenib combined with venetoclax and azacitidine for the treatment of newly diagnosed IDH1-mutant Acute Myeloid Leukemia: A prospective, two cohorts, multicenter study

View Full Paper
Ask AI
Bookmark
Share

Authors

HDHaiping DaiDWDepei WuSCSuning Chen

Discussion

Loading...

Member takes

Overview

Prospective analysis shows improved outcomes in acute myeloid leukemia, suggesting new treatment strategies may enhance quality of life.

Key Points

  • Survival rates improved significantly in acute myeloid leukemia with therapy involving Ivosidenib, Venetoclax, and Azacitidine.
  • This study report highlights a composite complete remission rate, vital for assessing treatment success in patients.
  • The current trial addresses quality of life factors and adverse events during treatment for acute myeloid leukemia.
  • Findings may enable broader adoption of multi-drug regimens in treating IDH1-mutant AML patients in diverse populations.

Cite This Study

Dai et al. (2025) studied this question.

synapsesocial.com/papers/69362f714fa91c937236e1dchttps://doi.org/10.1182/blood-2025-8249
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1A phase II study of IDH1 inhibition with ivosidenib as maintenance therapy after ivosidenib, azacitidine, and venetoclax for Acute Myeloid Leukemia: Trial in progress2025
  2. 2Phase 3 Study of ivosidenib (IVO) and azacitidine (AZA) with or without venetoclax in adult patients with newly diagnosed IDH1-mutated AML or MDS/AML ineligible for intensive chemotherapy (EVOLVE-1)2025 · 3 citations
  3. 3Real-world overall survival in patients with Acute Myeloid Leukemia treated with ivosidenib plus azacitidine in the USA: Trinetx-based analysis2025 · 1 citations
  4. 4Updated response and safety analyses from a Phase 1 study of ivosidenib combined with intensive chemotherapy in patients with newly diagnosed (ND) Acute Myeloid Leukemia with isocitrate dehydrogenase (IDH)1 mutation2025 · 2 citations
  5. 5Real life study of ivosidenib in either monotherapy or combined with azacytidine for first line mutant IDH1 AML: A study from the french AML intergroup ALFA/filo2025 · 1 citations